(Circulation. 2005;112:2812-2820.)
© 2005 American Heart Association, Inc.
Heart Failure |
From the Departments of Cell Biology (N.V., M.B., S.U., X.Z., S.L.H., M.S.P.) and Cardiovascular Medicine (T.W., E.J.T., S.L.H., M.S.P.) and Center for Cardiovascular Diagnostics and Prevention (M.B., S.L.H.), Cleveland Clinic Foundation, Cleveland, Ohio; Free Radical and Radiation Biology Program, Department of Radiation Oncology, University of Iowa, Iowa City (D.R.S.); and Department of Medicine, University of Washington, Seattle (J.W.H.).
Correspondence to Marc S. Penn, MD, PhD, NC10, Departments of Cardiovascular Medicine and Cell Biology, Cleveland Clinic Foundation, NC10, 9500 Euclid Ave, Cleveland, OH 44195. E-mail pennm{at}ccf.org
Received February 10, 2005; revision received August 6, 2005; accepted August 11, 2005.
Background Inflammation after myocardial infarction (MI) heralds worse left ventricular (LV) function and clinical outcomes. However, whether inflammation affects LV function by extending myonecrosis and/or altering LV remodeling remains unknown. We hypothesized that cytotoxic aldehydes generated during oxidative stress may adversely affect remodeling and infarct size. One theoretical source of reactive aldehydes is oxidation of common
-amino acids by myeloperoxidase (MPO) released by leukocytes. However, a role for MPO in formation of aldehydes in vivo and the functional consequences of MPO-generated oxidants in ischemia/reperfusion models of MI have not been established.
Methods and Results In studies with cell types found in vascular tissue, MPO-oxidation products of glycine (formaldehyde) and threonine (acrolein) were the most cytotoxic. Mass spectrometry studies of myocardial tissue from murine models of acute MI (both chronic left anterior descending coronary artery ligation and ischemia/reperfusion injury) confirmed that MPO serves as a major enzymatic source in the generation of these cytotoxic aldehydes. Interestingly, although MPO-null mice experienced 35.1% (P<0.001) less LV dilation and a 52.2% (P<0.0001) improvement in LV function compared with wild-type mice 24 days after ischemia/reperfusion injury, no difference in infarct size between wild-type and MPO-null mice was noted.
Conclusions The present data separate inflammatory effects on infarct size and LV remodeling and demonstrate that MPO-generated oxidants do not significantly affect tissue necrosis after MI but rather have a profound adverse effect on LV remodeling and function.
This article has been cited by other articles:
![]() |
H. S. Deshmukh, A. McLachlan, J. J. Atkinson, W. D. Hardie, T. R. Korfhagen, M. Dietsch, Y. Liu, P. Y. P. Di, S. C. Wesselkamper, M. T. Borchers, et al. Matrix Metalloproteinase-14 Mediates a Phenotypic Shift in the Airways to Increase Mucin Production Am. J. Respir. Crit. Care Med., November 1, 2009; 180(9): 834 - 845. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. PENN and E. E. BAKKEN Heart-brain medicine: Update 2008 Cleveland Clinic Journal of Medicine, April 1, 2009; 76(Suppl_2): S5 - S7. [Full Text] [PDF] |
||||
![]() |
S. J. Nicholls and S. L. Hazen Myeloperoxidase, modified lipoproteins, and atherogenesis J. Lipid Res., April 1, 2009; 50(Supplement): S346 - S351. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Landmesser, K. C. Wollert, and H. Drexler Potential novel pharmacological therapies for myocardial remodelling Cardiovasc Res, February 15, 2009; 81(3): 519 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Shah, W. J. Kop, R. H. Christenson, D. B. Diercks, D. Kuo, S. Henderson, K. Hanson, M. R. Mehra, and C. R. deFilippi Lack of Diagnostic and Prognostic Utility of Circulating Plasma Myeloperoxidase Concentrations in Patients Presenting with Dyspnea Clin. Chem., January 1, 2009; 55(1): 59 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Ambler, Y. K. Hodges, G. M. Jones, C. S. Long, and L. D. Horwitz Prolonged administration of a dithiol antioxidant protects against ventricular remodeling due to ischemia-reperfusion in mice Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1303 - H1310. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. McEvoy, A.-G. Taylor, J. A. Zavadzkas, I. M. Mains, R. L. Ford, R. E. Stroud, L. B. Jeffords, C. U. Beck, S. T. Reeves, and F. G. Spinale Aprotinin Exerts Differential and Dose-Dependent Effects on Myocardial Contractility, Oxidative Stress, and Cytokine Release After Ischemia-Reperfusion Ann. Thorac. Surg., August 1, 2008; 86(2): 568 - 575. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nahrendorf, D. Sosnovik, J. W. Chen, P. Panizzi, J.-L. Figueiredo, E. Aikawa, P. Libby, F. K. Swirski, and R. Weissleder Activatable Magnetic Resonance Imaging Agent Reports Myeloperoxidase Activity in Healing Infarcts and Noninvasively Detects the Antiinflammatory Effects of Atorvastatin on Ischemia-Reperfusion Injury Circulation, March 4, 2008; 117(9): 1153 - 1160. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Luo, B. G. Hill, Y. Gu, J. Cai, S. Srivastava, A. Bhatnagar, and S. D. Prabhu Mechanisms of acrolein-induced myocardial dysfunction: implications for environmental and endogenous aldehyde exposure Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3673 - H3684. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Matthijsen, D. Huugen, N. T. Hoebers, B. de Vries, C. J. Peutz-Kootstra, Y. Aratani, M. R. Daha, J. W. C. Tervaert, W. A. Buurman, and P. Heeringa Myeloperoxidase Is Critically Involved in the Induction of Organ Damage after Renal Ischemia Reperfusion Am. J. Pathol., December 1, 2007; 171(6): 1743 - 1752. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Spagnoli, E. Bonanno, G. Sangiorgi, and A. Mauriello Role of Inflammation in Atherosclerosis J. Nucl. Med., November 1, 2007; 48(11): 1800 - 1815. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Li, A. C. Keenan, J. C. Young, M. J. Hall, Z. Pamuklar, E. M. Ohman, S. R. Steinhubl, and S. S. Smyth Effects of Unfractionated Heparin and Glycoprotein IIb/IIIa Antagonists Versus Bivalirdin on Myeloperoxidase Release From Neutrophils Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1850 - 1856. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.H. W. Tang, W. Tong, R. W. Troughton, M. G. Martin, K. Shrestha, A. Borowski, S. Jasper, S. L. Hazen, and A. L. Klein Prognostic Value and Echocardiographic Determinants of Plasma Myeloperoxidase Levels in Chronic Heart Failure J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2364 - 2370. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Wildsmith, C. J. Albert, D. S. Anbukumar, and D. A. Ford Metabolism of Myeloperoxidase-derived 2-Chlorohexadecanal J. Biol. Chem., June 23, 2006; 281(25): 16849 - 16860. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |